Zavegepant

(Zavzpret®)

Zavzpret®

Drug updated on 4/16/2024

Dosage FormNasal spray (intranasal; 10 mg)
Drug ClassCalcitonin gene-related peptide receptor antagonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the acute treatment of migraine with or without aura in adults.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated, with no liability accepted for reliance on it. Learn more.

  • Zavegepant (Zavzpret) is indicated for the acute treatment of migraine with or without aura in adults, showing promising efficacy and tolerability as an abortive treatment for episodic migraine.
  • Four systematic reviews/meta-analyses were analyzed to gather information on the safety and effectiveness of this drug compared to others used for similar indications.
  • Compared to lasmiditan, rimegepant, and ubrogepant, Zavegepant may be less effective at achieving immediate pain relief within 2 hours or sustaining pain relief over 24 hours. However, it appears that Zavegepant has a better safety profile than lasmiditan, which exhibits the highest risk of adverse events.
  • Among intranasal therapies, while butorphanol excels at 1-hour pain freedom and zolmitriptan displays high efficacy for pain freedom at two hours post-administration, Zavegepant nasal spray stands out due to its lower risk of adverse events, indicating a superior safety profile among these agents.
  • A study suggests that Zavegepant is more effective than placebo in achieving both short-term (pain freedom within two hours) and long-term outcomes (sustained pain freedom between 2 to 48 hours), although its effect on preventing relapse remains inconclusive.
  • The studies indicate that despite some alternatives like lasmiditan showing higher immediate efficacy rates, the overall balance between effectiveness against migraines - especially with rapid onset when administered nasally - coupled with fewer side effects, makes Zavzpret a compelling choice, particularly among adult patients who prioritize convenience alongside fewer side effects.